Subscribe To

Price Alert Latest News Economic Calendar News

CNVCF / BioHarvest Sciences projects 2023 revenue to more than triple as its biotech innovation pays off

BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has said it is estimating 2023 revenue to be between $17 million and $20 million, representing growth of at least three times over 2022. The Vancouver-based company said revenue for 2022 is now estimated to be $5.5 million to $5.7 million, meeting the guidance range it provided in the first quarter of the year. Read More

Demo Live Account See Partner Details

Content Topics

Bioharvest

Sciences

Projects

2023

Revenue

Than

Triple

Biotech

Innovation

Stock

CNVCF

Posted: Dec 15 2022, 08:03

Author Name: Proactive Investors

CNVCF News

By Proactive Investors
October 30, 2023

BioHarvest Sciences raises C$11.78 million in first tranche of private placement

BioHarvest Sciences Inc said it has closed the first tranche of its previously-annouced C$13.5 million non-brokered private placement of convertible n

By Proactive Investors
October 19, 2023

BioHarvest Sciences to raise up to $12M in convertible notes financing

BioHarvest Sciences Inc has announced its intention to raise proceeds of up to $12 million in a non-brokered private placement of convertible notes.�

By Proactive Investors
October 10, 2023

BioHarvest Sciences announces Health Canada license for VINIA sales in Canada

BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced it has received a Canadian product license for VINIA from Health Canada's Natural and Non-P

By Seeking Alpha
September 7, 2023

BioHarvest Sciences Inc. (CNVCF) Q2 Shareholder Presentation Call Transcript

BioHarvest Sciences Inc. (OTCQB:CNVCF) Q2 Shareholder Presentation Call September 6, 2023 2:30 PM ET Company Participants Justin Meiklem - Investor Re

By Proactive Investors
September 6, 2023

BioHarvest Sciences achieves 'significant milestone' with US sales of VINIA topping US$1M in August

BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has announced that monthly US sales of its flagship VINIA product surpassed $1 million in August 2023.

By Proactive Investors
June 30, 2023

BioHarvest Sciences CMO shares personal connection to VINIA supplement in Collision keynote

BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) chief medical officer Dr. Brian Cornblatt can speak to the effectiveness of the company's red grape-ba

By Proactive Investors
June 28, 2023

BioHarvest Sciences revolutionizing health industry with botanical synthesis

Imagine a world where we harness the power of plants to improve human wellness without harming the environment. Israeli biotech innovator BioHarvest S

By Seeking Alpha
June 22, 2023

BioHarvest Sciences Inc. (CNVCF) Q2 Marketing and Performance Update Call Transcript

BioHarvest Sciences Inc. (OTCQB:CNVCF) Q2 Marketing and Performance Update Conference Call June 22, 2023 2:00 PM ET Company Participants Justin Meikle

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.